Peer Review History
| Original SubmissionJanuary 9, 2025 |
|---|
|
Dear Dr. Couderc, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. I agree with the reviewers. Please see the reviewers' suggestions and make the changes as suggested and answer the reviewers' questions. Please submit your revised manuscript by Mar 09 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alexandre Morais Nunes, Ph.D. Academic Editor PLOS ONE Journal requirements:-->--> -->-->When submitting your revision, we need you to address these additional requirements.-->--> -->-->1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at -->-->https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and -->-->https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.-->--> -->-->2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]-->--> -->-->Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).-->--> -->-->For example, authors should submit the following data:-->--> -->-->- The values behind the means, standard deviations and other measures reported;-->-->- The values used to build graphs;-->-->- The points extracted from images for analysis.-->--> -->-->Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.-->--> -->-->If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.-->--> -->-->If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.-->--> -->-->3. Please include a copy of Table 1 which you refer to in your text on page 8.-->?> [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The paper presents an interesting and relevant topic. However, it suffers from several drawbacks that need to be corrected before its possible acceptance. - The abstract needs to be rewritten, especially clarify the background, after objectives. - I advise the authors to professionally proofread their manuscript prior to resubmitting. - Introduction is complet in the health area. However, I think it could better frame the problem under study, indicating more explicitly the factors that were at the basis of the research. - Methods chapter needs more specification of empirical work. For example, I would like to see a better characterization of the target population and sample in the empirical part - In structural terms, I suggest that the discussion should be combined with the results and that the conclusions should be in a “CONCLUSIONS” chapter. Reviewer #2: The study identifies a predominance of affluent female patients, likely influenced by the institute’s focus on breast cancer. However, it does not adequately explore the implications of this demographic concentration. Provide detailed information on recruitment strategies. Specify whether efforts were made to include a broader demographic, such as patients from varied socioeconomic backgrounds, men, or those with other cancer types. Explicitly discuss how this sample demographic may limit the generalizability of findings, particularly for less affluent, male, or geographically isolated populations. If data permits, include subgroup comparisons (e.g., by gender, socioeconomic status, or geography) to identify variations in teleconsultation experiences or outcomes. Exclusion of 5% of patients due to lack of internet access underlines inequities in teleconsultation availability. Suggest strategies such as providing technical equipment (e.g., tablets, mobile hotspots); establishing community telemedicine hubs for shared access; and offering telephonic consultations as a low-tech alternative. Discuss how these findings could inform policies aimed at reducing the digital divide, such as public-private partnerships to improve digital infrastructure in underserved areas or subsidies for patients to access necessary technology. The study briefly mentions educational, cultural, and medical capital but lacks depth on their influence on teleconsultation outcomes. Incorporate specific patient stories or quotes from interviews that highlight how these forms of capital impact engagement and satisfaction with teleconsultations. Provide actionable insights on how teleconsultation practices can be adapted to different social profiles. For instance, patients with lower digital literacy may benefit from tutorials or simplified interfaces, while those with high medical literacy may prefer in-depth discussions. The high mortality rate (64%) within three months of enrolment indicates delayed referrals to palliative care, limiting teleconsultation benefits. Investigate and discuss factors contributing to late referrals, such as healthcare provider hesitancy, lack of patient awareness, or systemic delays. Advocate for integrating palliative care earlier in the oncology care pathway, emphasising benefits beyond end-of-life care. Reflect on how late-stage enrolment may have constrained patients’ ability to adapt to teleconsultations, potentially skewing satisfaction or utility perceptions. The absence of standardised quantitative outcome measures weakens the study's conclusions. Include quantitative tools such as patient satisfaction surveys for a standardised view of teleconsultation acceptance, health-related quality of life measures to evaluate broader impacts, and symptom management success rates or reduced hospitalisations. Discuss how these metrics corroborate or challenge qualitative findings, adding rigour to the study’s conclusions. Gendered socialisation is mentioned but not explored in detail regarding its influence on teleconsultation outcomes. Elaborate on how gender roles and expectations may shape teleconsultation engagement. For instance, women may be more accustomed to caregiving roles, influencing their comfort with digital health tools, and communication styles may vary by gender, affecting the dynamics of virtual consultations. Provide evidence or examples from interviews or observations that highlight these gendered differences in teleconsultation experiences. While identifying barriers like digital literacy and connectivity, the study does not propose concrete solutions. Discuss initiatives such as training programs for patients and carers to improve digital literacy and developing user-friendly telehealth platforms with intuitive interfaces. Highlight how healthcare systems and policymakers can address these barriers, including funding for digital tools or legislation to ensure equitable access to telemedicine. The three-month study duration limits insights into the sustained impact of teleconsultations. Suggest follow-up studies spanning six months to a year to assess long-term outcomes, including patient satisfaction, clinical effectiveness, and cost-efficiency. Discuss potential issues in maintaining engagement over time, such as digital fatigue, evolving patient needs, or technological challenges. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Andreia Matos Reviewer #2: Yes: Ricardo de Moraes e Soares ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Dear Dr. Couderc, plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alexandre Morais Nunes, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: No ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: N/A Reviewer #3: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes ********** Reviewer #2: The study provides rich qualitative insights; it lacks quantitative data that could enhance its generalisability. A mixed-methods approach, incorporating statistical analysis on teleconsultation adherence rates, patient outcomes, and healthcare resource utilisation, would strengthen its findings. Additionally, the study focuses exclusively on women, which limits its applicability to male patients, whose communication styles and healthcare engagement may differ. Future research should explore gendered differences in telemedicine adoption and effectiveness. The concept of the sentinel patient is useful but may not apply to all palliative care patients. The study predominantly examines patients who are already familiar with medical systems and possess significant health literacy. This overlooks populations with lower medical capital, such as those from disadvantaged socioeconomic backgrounds or with limited prior healthcare engagement. Additionally, while the study suggests that all patients connected without major technical difficulties, it does not explore those who refused teleconsultations or faced digital barriers. This omission risks presenting an overly optimistic view of telemedicine’s accessibility. The study briefly mentions that older patients had slight hesitations regarding digital tools; it does not provide a more profound analysis of technological barriers. Questions remain regarding i) internet availability in rural areas; ii) the impact of cognitive decline on telemedicine efficacy; and iii) the usability of teleconsultation platforms for those with limited digital literacy. A more detailed discussion of these barriers would provide a more nuanced understanding of telemedicine’s limitations. The study highlights the convenience of telemedicine; it does not fully address the ethical and emotional implications of conducting palliative care remotely. End-of-life care is deeply personal, and face-to-face interactions often provide comfort to patients and families. The study could have explored i) whether patients felt a diminished sense of empathy or emotional connection in teleconsultations; ii) how physicians adapted their communication styles to convey empathy via screens; and iii) the psychological impact of receiving difficult news remotely. Reviewer #3: Manuscript Title: The benefits of palliative care follow-up combining day hospital and telemedicine Thank you for the opportunity to review this revised manuscript. The topic is highly relevant and addresses a pressing issue in modern palliative care, namely how to provide continuity and access amidst limited resources. The hybrid model of day hospital visits supplemented with monthly teleconsultations is well aligned with current clinical trends and the authors have clearly invested significant effort into both the intervention and its reporting. However, several major concerns remain regarding the scientific structure, methodological transparency, and framing of results. These must be rigorously addressed before, in my opinion, the manuscript can be considered for publication. 1. Structure: Results and Discussion should be separated The current manuscript blends results and interpretation into a single narrative section. This format is not appropriate for a mixed-methods empirical study. It undermines the clarity and reproducibility of findings and makes it difficult to assess which conclusions are supported by data. The result is a blurring of the line between what was observed and what is interpreted, which compromises clarity, reproducibility, and transparency. Suggestion: Clearly separate the Results (quantitative and qualitative, with descriptive reporting) from the Discussion (interpretive and reflective). This is essential to align with scientific conventions. 2. Methods section lacks sufficient detail The manuscript’s methodological reporting is insufficient for both quantitative and qualitative components. Quantitative: There is no information on item development, scale use, validation, or analytic plan. Statements such as “no correlation was observed” are unsupported. Qualitative: Thematic analysis is described only briefly. There is no mention of coding procedures, who performed the coding, whether any inter-rater discussion took place, or what software (if any) was used. Suggestion: Expand the Methods section to provide a clear, replicable account of both arms of data collection and analysis. Avoid making statistical claims unless supported by actual analysis. The Methods section should follow a golden thread that is complemented by the results (i.e. in the same logical order). 3. Title Overstates the Study’s Scope The current title suggests demonstrated “benefits” from the hybrid care model. In reality, this is a short-term, small-sample feasibility and acceptability study with descriptive data and no comparative outcome evaluation. Suggestion: Revise the title to more accurately reflect the study’s scope—e.g., “Feasibility of a Hybrid Day Hospital and Teleconsultation Follow-Up Model in Palliative Oncology” or similar. 4. Interpretation should be tempered The manuscript occasionally draws conclusions not directly supported by the data. For example, claims about symptom management or reduction in emergency admissions are suggestive at best and should be clearly framed as such. Similarly, the interesting “sentinel patient” framing from the sociological literature should be presented more cautiously, given the lack of comparison across patient groups. Suggestion: Reframe these interpretations as hypotheses or observations for further study, rather than demonstrated effects. 5. Qualitative reporting should be focused The inclusion of patient quotes is valuable, but currently some quotes are lengthy and repetitive. This can be streamlined to improve readability and thematic clarity. Suggestion: Shorten representative quotes where possible and consider a summary table of themes and sample quotes for structure and clarity. 6. Generalizability Limitations Need Further Emphasis The sample is small, skewed toward female and relatively affluent patients and drawn from a single institution. These limitations are acknowledged but should be discussed more directly in relation to the feasibility of broader implementation. The study population is likely to be highly selected (e.g., patients with access to digital tools, caregiver support, good pre-existing health system familiarity). Conclusion This is a valuable and well-motivated pilot study and I appreciate the authors’ clear dedication to improving care delivery. However, substantial revisions are required to meet basic standards of scientific reporting. I recommend major revision, with clear restructuring of the manuscript and strengthening of methods and framing. I would be willing to re-review a revised version that addresses these concerns. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: Yes: Ricardo de Moraes e Soares Reviewer #3: Yes: Patrick Altmann, MD ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-25-00301R2-->-->Palliative care follow-up for cancer patients combining day-hospital visits and telemedicine: what feasibility?-->-->PLOS One?> Dear Dr. Couderc, Please submit your revised manuscript by Feb 26 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alexandre Morais Nunes, Ph.D. Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: The revision turned out much better. While I believe reviewer 4's suggestion of a major revision is excessive, I ask that you address the methodological issues that the reviewer identified. [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #4: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #4: No ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #4: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #4: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #4: Yes ********** Reviewer #1: The authors have made all the suggested revisions. It is ready to be approved. I have nothing to add. I think it is aligned with the journal rules. Reviewer #4: The methodology is described in a valid manner. The text states that a feasibility assessment model was adopted. However, the adopted model was not aligned with the assumptions for conducting feasibility studies. The text is silent regarding the justification of the recruitment rate, retention parameters, acceptance thresholds, and feasibility criteria. The feasibility analysis is retrospective and descriptive. The situation limits the validity of the analysis and hinders the evaluation of the model's application. It is suggested that the feasibility outcomes be defined a priori, such as the completion rates of admissible teleconsultations, the proportion of eligible patients, and the acceptable rates of technical failures. It is also suggested that inferences regarding feasibility be related to predefined benchmarks, and in case of impossibility, the limitations should be acknowledged and that feasibility was assessed in an exploratory rather than systematic manner. The inclusion criterion, estimated life expectancy ≥3 months, is not operationalised or justified, and the imprecision is evidenced by the high mortality rate (64%). The situation raises concerns about the validity of the selection and adequacy of the eligibility assessment, which affects the interpretation of the results. It is suggested that the clinical criteria for estimating life expectancy be described. It is also suggested to discuss the implications of inaccurate prognostication on the validity of the study. The limitations and biases should be discussed, and the sample reformulated. Quantitative methods depend on specific items from the questionnaire, which have not been validated or subjected to psychometric evaluations. The text is also silent regarding the reliability, construct validity, or consistency of the composite indices. The conclusions about the patients' behaviours, reassurance, and perceived benefits are based on measures of uncertain validity. It is suggested to describe the assumptions behind the construction of the questionnaire or, alternatively, to acknowledge the lack of validation, which represents a significant methodological limitation. It is also suggested to exercise more moderation in interpreting the questionnaire results and that the conclusions be limited solely to the observed evidence. The statistical analyses are insufficient to support the inferences of absence of associations between demographic variables and the feasibility or acceptability of teleconsultation. Due to the sample size, skewed distributions, and limited statistical power, non-significant results cannot be interpreted as evidence of the absence of effect. It is suggested to reformulate the text. It is also suggested to replace definitive terms (did not influence) with more probabilistic terms (no statistically detected association in the sample), acknowledging the risk of Type II error. The text should avoid conclusions related to equity that are not supported by the obtained results. Qualitative analysis lacks methodological rigour to support conceptual interpretations. The description of the results suggests the existence of beneficial contributions from teleconsultation. However, the data only allow us to state that teleconsultation enabled clinical interventions in individual cases but do not allow us to conclude that it caused improvements in clinical outcomes or that it prevented hospitalisations. Given the absence of comparison terms, the interpretations of the results exceed the evidentiary strength of the data. It is suggested to reclassify the examples as illustrations of descriptive cases rather than observed evidence. The interpretations have a hypothetical nature and are speculative. There is an observed confusion between feasibility, acceptability, and perceived benefit throughout the Results and Discussion sections. Although patient satisfaction and positive perceptions have been documented, the results do not equate to feasibility in the target population, especially considering the exclusion of patients without digital access and those who passed away early. It is suggested that feasibility (implementation capacity), acceptability (patient perception), and perceived benefit (subjective value) be described as distinct constructs with their respective limitations separated. It is also suggested that evidence be emphasised. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Andreia Matos Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 3 |
|
Palliative care follow-up for cancer patients combining day-hospital visits and telemedicine: what feasibility? PONE-D-25-00301R3 Dear Dr. Bettina C Couderc We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Alexandre Morais Nunes, Ph.D. Academic Editor PLOS One Additional Editor Comments (optional): The authors submitted a second revised version, incorporating a comprehensive set of corrections that address the comments from both reviewers. In addition to attaching the new final version, they took the trouble to include a version with tracked changes to facilitate the evaluation of the revisions. As the editor, I compared the two versions and believe that after long and demanding revisions, the paper is ready to be approved. Reviewers' comments: In the previous review, Reviewer 1 had already accepted the work, albeit with minor suggestions. Reviewer 2 demanded more changes (even somewhat excessively), which the authors accepted. |
| Formally Accepted |
|
PONE-D-25-00301R3 PLOS One Dear Dr. Couderc, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Alexandre Morais Nunes Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .